em. prof. dr. Geert Leroux-Roels
- ORCID iD
- 0000-0001-5968-2542
Show
Sort by
-
- Journal Article
- A1
- open access
Safety and immunogenicity of a carbohydrate fatty acid monosulphate ester adjuvant combined with a low-dose quadrivalent split-virion inactivated influenza vaccine : a randomised, observer-blind, active-controlled, first-in-human, phase 1 study
-
Safety and immunogenicity of the live-attenuated hRVFV-4s vaccine against Rift Valley fever in healthy adults : a dose-escalation, placebo-controlled, first-in-human, phase 1 randomised clinical trial
-
- Journal Article
- A1
- open access
Immune responses in healthy adults elicited by a bivalent norovirus vaccine candidate composed of GI.4 and GII.4 VLPs without adjuvant
-
- Journal Article
- A1
- open access
Immunogenicity, safety, and preliminary efficacy evaluation of OVX836, a nucleoprotein-based universal influenza A vaccine candidate : a randomised, double-blind, placebo-controlled, phase 2a trial
-
- Journal Article
- A1
- open access
Human immunity and susceptibility to influenza A(H3) viruses of avian, equine, and swine origin
-
- Journal Article
- A1
- open access
Double-blind, placebo-controlled, dose-escalating study evaluating the safety and immunogenicity of an epitope-specific chemically defined nanoparticle RSV vaccine
-
- Journal Article
- A1
- open access
A human monoclonal antibody against HBsAg for the prevention and treatment of chronic HBV and HDV infection
-
- Journal Article
- A2
- open access
Safety and immunogenicity of mRNA-LNP COVID-19 vaccine CVnCoV in Latin American adults : a phase 2 randomized study
-
- Journal Article
- A1
- open access
Harmonization and qualification of intracellular cytokine staining to measure influenza-specific CD4+ T cell immunity within the FLUCOP consortium
-
- Journal Article
- A1
- open access
A randomized, double-blind, placebo-controlled, dose-escalating phase I trial to evaluate safety and immunogenicity of a plant-produced, bivalent, recombinant norovirus-like particle vaccine